Ceres Inc (CERE): Price and Financial Metrics
CERE Price/Volume Stats
| Current price | $42.14 | 52-week high | $43.59 |
| Prev. close | $41.60 | 52-week low | $19.59 |
| Day low | $41.70 | Volume | 1,282,800 |
| Day high | $42.21 | Avg. volume | 1,523,868 |
| 50-day MA | $41.93 | Dividend yield | N/A |
| 200-day MA | $32.53 | Market Cap | 7.65B |
CERE Stock Price Chart Interactive Chart >
Ceres Inc (CERE) Company Bio
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies.
Latest CERE News From Around the Web
Below are the latest news stories about CEREVEL THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate CERE as an investment opportunity.
The 7 Most Undervalued Growth Stocks to Buy in DecemberStocks of a lot of well-known and historically great companies are on sale right now. |
The 3 Best Cheap Stocks to Buy in DecemberInvestors wanting to buy low and sell high should consider a position in one of these great companies whose shares have pulled back lately. |
$19 Billion in a Week: AbbVie Makes Two Big BetsThe drugmaker is doubling down on cancer and neurology as it seeks to replace falling revenue from its top sellers. |
LILM Stock Alert: Lilium Partners Up With LufthansaLilium stock is gaining on Thursday as investors in LILM react to a potential partnership with Lufthansa for eVTOLs in Europe. |
Why Is Cerevel Therapeutics (CERE) Stock Up 12% Today?Cerevel Therapeutics stock is climbing higher as CERE investors react to an $8.7 billion acquisition deal with AbbVie. |
CERE Price Returns
| 1-mo | -0.38% |
| 3-mo | -0.26% |
| 6-mo | 85.23% |
| 1-year | 60.53% |
| 3-year | 190.82% |
| 5-year | N/A |
| YTD | -0.61% |
| 2023 | 34.43% |
| 2022 | -2.71% |
| 2021 | 95.54% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...